Agenus Inc (AGEN) Stock Price, Quote & News

Company Profile

Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 674 4400

Fax: 781 674 4200

Website: www.agenusbio.com

Address:

3 Forbes Road, Lexington, United States

Biotechguy21 Jul. 15 at 10:07 PM

$AGEN look out below! what another amazing day!

1 · Reply

Biotechguy21 Jul. 15 at 10:07 PM

$INKT going much lower. ATM will be used to keep the company alive and then a RS just like $AGEN

0 · Reply

Jonnycricket Jul. 15 at 9:08 PM

$AGEN Look out for any Form 4s by Agen on Inkp tomorrow. It's possible that they would have to wait 2 business days to report. I don't really know how the reporting rules apply here, but one would assume that Agen's position in Inkp is an insider. However, the news on Friday really wasn't material; it just was interpreted as such. No one expected Inkp's gains. The one day wonders in biotech stocks are not unusual. We've had a few others this week too and they're biomemes

0 · Reply

Peaceouty Jul. 15 at 7:35 PM

$INKT @Biotechguy21 Is very emotional with $AGEN and $INKT what happened?

1 · Reply

Biotechguy21 Jul. 15 at 5:45 PM

$INKT rookie. you aren’t wise to the ways of this company and $AGEN

1 · Reply

docBNM Jul. 15 at 5:18 PM

$AGEN volume seemed to dry up on the move down so that’s a positive.

1 · Reply

Biotechguy21 Jul. 15 at 4:27 PM

$AGEN that’s why you are down 9% 👇👇👇🤡🤡🤡😂😂😂

1 · Reply

Moon37 Jul. 15 at 4:01 PM

$AGEN $INKT dont let these shorts fool you. ive been following for 6 years. in it for the long haul BO

0 · Reply

Moon37 Jul. 15 at 3:08 PM

$AGEN avengers assemble

0 · Reply

Moon37 Jul. 15 at 3:07 PM

$AGEN all that for a drop of blood?

0 · Reply

Agenus' BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3

Jun 17, 2025, 7:30 AM EDT - 4 weeks ago

Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology

Jun 10, 2025, 1:30 PM EDT - 5 weeks ago

Agenus Announces Virtual Annual Shareholders Meeting

Jun 4, 2025, 2:38 PM EDT - 5 weeks ago

Analyst Upgrades Agenus As Zydus Deal Alleviates Cash Overhang

Jun 3, 2025, 7:00 AM EDT - 6 weeks ago

Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus' Biologics Manufacturing in the US

May 30, 2025, 7:30 AM EDT - 6 weeks ago

Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

May 23, 2025, 3:09 PM EDT - 7 weeks ago

Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide

May 15, 2025, 10:40 AM EDT - 2 months ago

Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

May 12, 2025, 2:46 PM EDT - 2 months ago

Agenus Inc. (AGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 7:30 AM EDT - 2 months ago

Agenus Reports Q1 2025 Financial Results and Key Business Updates

May 12, 2025, 7:20 AM EDT - 2 months ago

Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer

Apr 29, 2025, 7:30 AM EDT - 2 months ago

Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

Apr 28, 2025, 3:30 PM EDT - 2 months ago

Agenus' BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR

Apr 25, 2025, 1:05 PM EDT - 2 months ago

Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025

Apr 23, 2025, 12:05 PM EDT - 2 months ago

Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025

Mar 25, 2025, 4:40 PM EDT - 4 months ago

Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025

Mar 19, 2025, 7:30 AM EDT - 4 months ago

Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation

Mar 11, 2025, 10:39 AM EDT - 4 months ago

Agenus Inc. (AGEN) Q4 2024 Earnings Call Transcript

Mar 11, 2025, 7:30 AM EDT - 4 months ago

Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

Feb 26, 2025, 4:48 PM EST - 4 months ago

Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications

Feb 25, 2025, 2:30 PM EST - 5 months ago

Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference

Feb 25, 2025, 8:26 AM EST - 5 months ago

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:33 AM EST - 5 months ago

Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting

Feb 23, 2025, 7:38 PM EST - 5 months ago

CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 5 months ago

Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting

$Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas$

Jan 29, 2025, 12:37 PM EST - 5 months ago

Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Jan 22, 2025, 2:48 PM EST - 6 months ago

Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease

Dec 18, 2024, 7:30 AM EST - 7 months ago

Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers

Dec 5, 2024, 7:30 AM EST - 7 months ago

Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs

Nov 27, 2024, 8:15 AM EST - 8 months ago

Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment

Nov 12, 2024, 10:41 AM EST - 8 months ago

Agenus Inc. (AGEN) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 7:00 AM EST - 8 months ago

Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development

Nov 7, 2024, 10:00 AM EST - 8 months ago

Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024

Nov 5, 2024, 7:30 AM EST - 9 months ago

Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update

Nov 4, 2024, 11:00 AM EST - 9 months ago

November 5 Deadline: Agenus Inc Is Being Sued For Defrauding The Public And Affected Shareholders Are Urged To Contact The Schall Law Firm

Nov 2, 2024, 11:00 AM EDT - 9 months ago

Agenus Inc Is Being Sued For Violating Securities Laws And Shareholders With Losses Are Urged To Contact The Schall Law Firm

Oct 30, 2024, 6:30 PM EDT - 9 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Agenus

Biotechguy21 Jul. 15 at 10:07 PM

$AGEN look out below! what another amazing day!

1 · Reply

Biotechguy21 Jul. 15 at 10:07 PM

$INKT going much lower. ATM will be used to keep the company alive and then a RS just like $AGEN

0 · Reply

Jonnycricket Jul. 15 at 9:08 PM

0 · Reply

Peaceouty Jul. 15 at 7:35 PM

$INKT @Biotechguy21 Is very emotional with $AGEN and $INKT what happened?

1 · Reply

Biotechguy21 Jul. 15 at 5:45 PM

$INKT rookie. you aren’t wise to the ways of this company and $AGEN

1 · Reply

docBNM Jul. 15 at 5:18 PM

$AGEN volume seemed to dry up on the move down so that’s a positive.

1 · Reply

Biotechguy21 Jul. 15 at 4:27 PM

$AGEN that’s why you are down 9% 👇👇👇🤡🤡🤡😂😂😂

1 · Reply

Moon37 Jul. 15 at 4:01 PM

$AGEN $INKT dont let these shorts fool you. ive been following for 6 years. in it for the long haul BO

0 · Reply

Moon37 Jul. 15 at 3:08 PM

$AGEN avengers assemble

0 · Reply

Moon37 Jul. 15 at 3:07 PM

$AGEN all that for a drop of blood?

0 · Reply

neversurrender2024 Jul. 15 at 2:42 PM

$AGEN $INKT investors realizing they were taking for a ride.....both going much lower!

0 · Reply

Biotechguy21 Jul. 15 at 2:41 PM

$AGEN what a great day already! $INKT going much lower. Same old story with these two pos stocks. SHs getting take to the cleaners 🤡🤡🤡😂😂😂💩💩💩💩

0 · Reply

Doom_Gloom_AR Jul. 15 at 2:36 PM

$AGEN coiling before it moves into the gap at around $8

0 · Reply

neversurrender2024 Jul. 15 at 2:36 PM

$INKT $AGEN its going lower folks,$26 by end of day.....

0 · Reply

neversurrender2024 Jul. 15 at 2:24 PM

$INKT $AGEN at this pace $7 revisited soon....get out while you can!

0 · Reply

Biotechguy21 Jul. 15 at 1:48 PM

$INKT look out below for this! Just like $AGEN it will go right back down. Endless atm activity coming

0 · Reply

neversurrender2024 Jul. 15 at 1:37 PM

$INKT $AGEN mink back to $7

1 · Reply

Moon37 Jul. 15 at 1:03 PM

$AGEN doesnt it seem so familiar? It’s almost like we went back in time … $6.50 price last time you tried to snap me out of existence…. i dont think its working out for you this time around

0 · Reply

Moon37 Jul. 15 at 12:51 PM

$AGEN you forgot who i am? Its been five years im baaaaack. and this time i brought a friend

0 · Reply

Biotechguy21 Jul. 15 at 11:44 AM

$INKT $AGEN dilution to all SHs!!!!!

0 · Reply

Moon37 Jul. 15 at 12:33 AM

$AGEN oh there something coming alright…

0 · Reply

Biotechguy21 Jul. 14 at 11:22 PM

$AGEN we all know what’s coming next. Stay tuned as they say!

0 · Reply

Market Cap	193.56M
Revenue (ttm)	103.46M
Net Income (ttm)	-227.21M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	3.81
Profit Margin	-219.61%
Debt to Equity Ratio	-0.10

Volume	1,267,400
Avg Vol	1,384,180
Day's Range	N/A - N/A
Shares Out	27.42M
Stochastic %K	83%
Beta	1.51
Analysts	Sell
Price Target	$11.50